Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Conditions
Brief summary
Primary Objective: To evaluate the efficacy of dupilumab 300 mg every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion (NC)/obstruction severity and endoscopic nasal polyp score (NPS) in participants with bilateral nasal polyps (NP). In addition for Japanese participants, reduction in computed tomography (CT) scan opacification of the sinuses was a co-primary objective. Secondary Objectives: * To evaluate the efficacy of dupilumab in improving total symptoms score. * To evaluate the efficacy of dupilumab in improving sense of smell. * To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (primary objective for Japanese participants). * To evaluate ability of dupilumab in reducing proportion of participants who required treatment with systemic corticosteroids (SCS) or surgery for NP. * To evaluate the effect of dupilumab on participant reported outcomes and health related quality of life. * To evaluate the efficacy of dupilumab 300 mg q2w up to Week 52. * To evaluate the efficacy of dupilumab 300 mg q2w up to Week 24 followed by 300 mg every 4 weeks (q4w) up to Week 52. * To evaluate the effect of dupilumab in the subgroups of participants with prior surgery and comorbid asthma including non-steroid anti-inflammatory drug exacerbated respiratory disease. * To evaluate the safety of dupilumab in participants with bilateral NP. * To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatment emergent anti-drug antibodies.
Detailed description
The total study duration per participant was up to 68 weeks that consisted of a 4-weeks run-in period, 52-weeks treatment period, and a 12-weeks post treatment period.
Interventions
Pharmaceutical form: Solution Route of administration: Subcutaneous
DRUGPlacebo
Pharmaceutical form: Solution Route of administration: Subcutaneous
DRUGMometasone furoate nasal spray
Pharmaceutical form: Suspension Route of administration: Intranasal
Sponsors
Regeneron Pharmaceuticals
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * Participants with bilateral sino-nasal polyposis that despite prior treatment with SCS anytime within the past 2 years; and/or had a medical contraindication/intolerance to SCS; and/or had prior surgery for NP at the screening visit, had: * An endoscopic bilateral NPS at Visit 1 (V1) of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity). * Ongoing symptoms (for at least 8 weeks before V1) of NC/blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior). * Signed written informed consent.
Exclusion criteria
* Participants \<18 years of age. * Participant who had been previously treated in dupilumab studies. * Participant who had taken: * Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever was longer. * Any experimental monoclonal antibody within 5 half-lives or within 6 months before V1 if the half-life was unknown. * Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1. * Participants who received leukotriene antagonists/modifiers at V1 unless they were on a continuous treatment for at least 30 days prior to V1. * Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period. * Participants who underwent any and/or sinus surgery (including polypectomy) within 6 months before V1. * Participants who had a sino-nasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS. * Participants with conditions/concomitant diseases making them non evaluable at V1 or for the primary efficacy endpoint such as: * Antrochoanal polyps, * Nasal septal deviation that would occlude at least one nostril, * Acute sinusitis, nasal infection or upper respiratory infection, * Ongoing rhinitis medicamentosa, * Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis),Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, concomitant cystic fibrosis, * Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis. * Participants with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.). * Participants with forced expiratory volume 50% or less (of predicted normal). * Participants who received concomitant treatment prohibited in the study. * Treatment with a live (attenuated) vaccine within 4 weeks before the baseline visit. * Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit. * History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening. * Positive with hepatitis B surface antigen or hepatitis C antibody at the screening visit. * Active chronic or acute infection requiring systemic treatment within 2 weeks before the baseline visit. * Known or suspected history of immunosuppression. * Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study. * Women unwilling to use adequate birth control, if of reproductive potential and sexually active. The above information was not intended to contain all considerations relevant to a Participant's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score | Baseline, Week 24 | NC symptom severity was assessed by the participants on a daily basis from visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Least squares (LS) means and standard error (SE) were obtained from Analysis of covariance (ANCOVA) model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 24 in Nasal Polyp Score | Baseline, Week 24 | NPS: sum of right, left nostril scores, evaluated by nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity; lower score = smaller sized polyps. Total NPS: sum of right and left nostril scores, ranges from 0 (no polyps) to 8 (large polyps), higher score = more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score | Baseline, Week 24 | The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily | Baseline, Week 24 | The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores | Baseline, Week 24 | The SNOT-22 is a validated questionnaire was used to assess the impact of chronic rhinosinusitis phenotype with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Nasal Polyp Score | Baseline, Week 52 | NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. |
| Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score | Baseline, Week 52 | NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. |
| Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores | Baseline, Week 52 | The SNOT-22 is a validated questionnaire that was used to assess the impact of CRSwNP on HRQoL. It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. |
| Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method | Baseline up to 52 weeks | Rescue treatment was defined as usage of systemic corticosteroids (SCS) or NP surgery (actual or planned) during the treatment period. Rescue treatment included: * SCS: betamethasone, deflazacort, dexamethasone, dexamethasone sodium phosphate, hydrocortisone, meprednisone, methylprednisolone, methylprednisolone sodium succinate, prednisolone, prednisolone sodium succinate, prednisone, stelamin, triamcinolone, and triamcinolone acetonide. * Sino-nasal surgery for nasal polyps when there was worsening of signs and/or symptoms during the study. Estimate of percentage of participants with event by Week 52 was obtained using Kaplan-Meier method. |
| Change From Baseline at Week 52 in Total Symptom Score | Baseline, Week 52 | The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score | Baseline, Week 52 | The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell | Baseline, Week 52 | The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score | Baseline, Week 52 | The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis | Baseline, Week 24 | The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters VAS the answer to the question, How troublesome are your symptoms of your rhinosinusitis? The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis | Baseline, Week 52 | The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters VAS the answer to the question, How troublesome are your symptoms of your rhinosinusitis? The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF) | Baseline, Week 24 | NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute. Higher NPIF values were indicative of better nasal air flow. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score | Baseline, Week 24 | Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score | Baseline, Week 52 | Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. |
| Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period | Baseline to Week 52 | SCS included: betamethasone, deflazacort, dexamethasone, dexamethasone sodium phosphate, hydrocortisone, meprednisone, methylprednisolone, methylprednisolone sodium succinate, prednisolone, prednisolone sodium succinate, prednisone, stelamin, triamcinolone, and triamcinolone acetonide. For every participant, the total dose was calculated as (prescribed total daily dose\*duration of SCS use). Then, mean of the total dose of 64 participants (placebo group), 17 participants (dupilumab 300 mg q2w then q4w) and 22 participants (dupilumab 300 mg q2w) was derived. |
| Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant | Baseline to Week 52 | Rescue treatment was defined as usage of SCS or NP surgery (actual or planned) during the treatment period. SCS Rescue intake duration was defined as the duration (in days) from start of SCS rescue medication till the end of SCS rescue treatment. |
| Changed From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma | Baseline, Week 24 | FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma | Baseline, Week 52 | FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma | Baseline, Week 24 | ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment, asthma status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma | Baseline, Week 52 | ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment, asthma status, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma | Baseline, Week 24 | NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma | Baseline, Week 52 | NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery | Baseline, Week 24 | NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery | Baseline, Week 52 | NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates. |
| Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma | Baseline, Week 24 | NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma | Baseline, Week 52 | NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. |
| Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery | Baseline, Week 24 | NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery | Baseline, Week 52 | NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. |
| Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma | Baseline, Week 24 | The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma | Baseline, Week 52 | The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. |
| Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery | Baseline, Week 24 | The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery | Baseline, Week 52 | The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates. |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Baseline up to 84 days after last dose of study drug (up to 64 weeks) | An Adverse Event (AE) was defined as any untoward medical occurrence that did not necessarily have to have a causal relationship with the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of drug until 84 days following the last administration of drug. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. |
| Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score | Baseline, Week 24 | The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. NOTE: For Japan regulatory submission only, this endpoint is not included as a secondary outcome measure and is instead one of the co-primary outcome measures. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score | Baseline, Week 52 | The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). |
| Functional Dupilumab Concentration in Serum | Baseline, Week 2, Week 4, Week 16, Week 24, Week 40, End of treatment (Week 52), End of study (Week 64) | — |
| Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA) | Baseline to Week 52 | ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as a positive response in the ADA assay post first dose, when baseline results are negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that is greater-than or equal to 4-fold over baseline titer levels, when baseline results are positive. |
| Change From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score | Baseline, Week 24 | The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
| Change From Baseline at Week 24 in Total Symptom Score (TSS) | Baseline, Week 24 | The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments. |
Countries
Argentina, Australia, Belgium, Canada, Chile, Israel, Japan, Mexico, Portugal, Russia, Spain, Sweden, Turkey (Türkiye), United States
Participant flow
Recruitment details
Study participants were involved in the study from 28 November 2016 to 16 November 2018 at 117 centers in 14 countries. A total of 806 participants were screened, of which 448 participants were enrolled and randomized to receive dupilumab 300 mg or placebo. A total of 358 participants had screen failures due to failure to meet inclusion criteria.
Pre-assignment details
Randomization was stratified according to asthma and/or non-steroidal anti-inflammatory drug exacerbated respiratory disease (NSAID-ERD) history (yes/no), prior nasal polyps (NP) surgery (yes or not), and country.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose. | 153 |
| Dupilumab 300 mg q2w Then q4w Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50. | 145 |
| Dupilumab 300mg q2w Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose. | 150 |
| Total | 448 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 4 | 1 | 2 |
| Overall Study | Did Not Met Eligibility Criteria | 1 | 0 | 0 |
| Overall Study | Lack of Efficacy | 4 | 1 | 0 |
| Overall Study | Lost to Follow-up | 1 | 0 | 0 |
| Overall Study | Protocol Violation | 1 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 6 | 3 | 3 |
Baseline characteristics
| Characteristic | Placebo | Total | Dupilumab 300mg q2w | Dupilumab 300 mg q2w Then q4w |
|---|---|---|---|---|
| Age, Continuous | 51.67 years STANDARD_DEVIATION 12.66 | 51.95 years STANDARD_DEVIATION 12.45 | 51.91 years STANDARD_DEVIATION 11.88 | 52.28 years STANDARD_DEVIATION 12.87 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 40 Participants | 132 Participants | 50 Participants | 42 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 113 Participants | 315 Participants | 100 Participants | 102 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Nasal Congestion/Obstruction (NC) Symptom Severity Score | 2.38 score on a scale STANDARD_DEVIATION 0.54 | 2.43 score on a scale STANDARD_DEVIATION 0.59 | 2.48 score on a scale STANDARD_DEVIATION 0.62 | 2.44 score on a scale STANDARD_DEVIATION 0.59 |
| Nasal Polyp Score (NPS) | 5.96 score on a scale STANDARD_DEVIATION 1.21 | 6.10 score on a scale STANDARD_DEVIATION 1.21 | 6.07 score on a scale STANDARD_DEVIATION 1.22 | 6.29 score on a scale STANDARD_DEVIATION 1.2 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 3 Participants | 12 Participants | 7 Participants | 2 Participants |
| Race/Ethnicity, Customized Asian/Oriental | 18 Participants | 54 Participants | 17 Participants | 19 Participants |
| Race/Ethnicity, Customized Black/of African descent | 3 Participants | 7 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Caucasian/White | 128 Participants | 372 Participants | 124 Participants | 120 Participants |
| Race/Ethnicity, Customized Multiple | 1 Participants | 2 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Female | 58 Participants | 169 Participants | 53 Participants | 58 Participants |
| Sex: Female, Male Male | 95 Participants | 279 Participants | 97 Participants | 87 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 150 | 1 / 148 | 0 / 149 |
| other Total, other adverse events | 111 / 150 | 95 / 148 | 90 / 149 |
| serious Total, serious adverse events | 16 / 150 | 12 / 148 | 8 / 149 |
Outcome results
Primary
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score
NC symptom severity was assessed by the participants on a daily basis from visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Least squares (LS) means and standard error (SE) were obtained from Analysis of covariance (ANCOVA) model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: The analysis was performed on intent-to-treat (ITT) population which included all randomized participants who were analyzed according to the treatment group allocated by randomization. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score | -0.38 score on a scale | Standard Error 0.07 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score | -1.25 score on a scale | Standard Error 0.06 |
Comparison: Data was analyzed using a hybrid method of the worst-observation carried forward (WOCF) and multiple imputation (MI). The imputed completed data were analyzed by fitting ANCOVA model with the corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-1.03, -0.71]ANCOVA
Primary
Change From Baseline at Week 24 in Nasal Polyp Score
NPS: sum of right, left nostril scores, evaluated by nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity; lower score = smaller sized polyps. Total NPS: sum of right and left nostril scores, ranges from 0 (no polyps) to 8 (large polyps), higher score = more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Nasal Polyp Score | 0.10 score on a scale | Standard Error 0.14 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Nasal Polyp Score | -1.71 score on a scale | Standard Error 0.11 |
Comparison: Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-2.1, -1.51]ANCOVA
Secondary
Changed From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma and had available data for this outcome measure. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Changed From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma | -0.05 liters | Standard Error 0.05 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Changed From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma | 0.17 liters | Standard Error 0.04 |
Secondary
Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores
The SNOT-22 is a validated questionnaire was used to assess the impact of chronic rhinosinusitis phenotype with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores | -10.40 score on a scale | Standard Error 1.61 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores | -27.77 score on a scale | Standard Error 1.26 |
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-20.87, -13.85]ANCOVA
Secondary
Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma
ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment, asthma status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma and had available data for this outcome measure. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma | 0.08 score on a scale | Standard Error 0.09 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma | -0.78 score on a scale | Standard Error 0.07 |
Secondary
Change From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score
The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable). All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score | 3.91 score on a scale | Standard Error 1.5 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score | 10.83 score on a scale | Standard Error 1.16 |
Secondary
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma
NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma | -0.39 score on a scale | Standard Error 0.09 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma | -1.36 score on a scale | Standard Error 0.07 |
Secondary
Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery
NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on a subset of participants which included all randomized participants with prior NP surgery history.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -0.27 score on a scale | Standard Error 0.1 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -1.30 score on a scale | Standard Error 0.08 |
Secondary
Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)
NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute. Higher NPIF values were indicative of better nasal air flow. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Data for this outcome measure was planned to be analyzed for the combined population of participants who received dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF) | 18.65 liters per minute | Standard Error 3.95 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF) | 55.29 liters per minute | Standard Error 3.08 |
Secondary
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma
NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma | 0.13 score on a scale | Standard Error 0.17 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma | -1.88 score on a scale | Standard Error 0.13 |
Secondary
Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery
NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on a subset of participants which included all randomized participants with prior NP surgery history and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery | 0.22 score on a scale | Standard Error 0.19 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -1.73 score on a scale | Standard Error 0.15 |
Secondary
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score
The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. NOTE: For Japan regulatory submission only, this endpoint is not included as a secondary outcome measure and is instead one of the co-primary outcome measures. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score | -0.09 score on a scale | Standard Error 0.31 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score | -5.21 score on a scale | Standard Error 0.24 |
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-5.8, -4.46]ANCOVA
Secondary
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma
The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma | -0.33 score on a scale | Standard Error 0.4 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma | -5.86 score on a scale | Standard Error 0.31 |
Secondary
Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery
The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on a subset of participants which included all randomized participants with prior NP surgery history and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -0.10 score on a scale | Standard Error 0.42 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -5.42 score on a scale | Standard Error 0.33 |
Secondary
Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score
Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score | -0.40 score on a scale | Standard Error 0.07 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score | -0.99 score on a scale | Standard Error 0.05 |
Secondary
Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily
The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily | -0.23 score on a scale | Standard Error 0.08 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily | -1.21 score on a scale | Standard Error 0.06 |
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-1.15, -0.81]ANCOVA
Secondary
Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score
The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score | -0.81 score on a scale | Standard Error 0.71 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score | 9.71 score on a scale | Standard Error 0.56 |
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [8.98, 12.07]ANCOVA
Secondary
Change From Baseline at Week 24 in Total Symptom Score (TSS)
The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Total Symptom Score (TSS) | -1.00 score on a scale | Standard Error 0.2 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Total Symptom Score (TSS) | -3.45 score on a scale | Standard Error 0.15 |
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-2.87, -2.02]ANCOVA
Secondary
Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis
The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters VAS the answer to the question, How troublesome are your symptoms of your rhinosinusitis? The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. All participants randomized to receive Dupilumab had been on 300 mg q2w regimen until Week 24 and analyzed as a pooled population for Week 24 assessments.
Time frame: Baseline, Week 24
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure. Data for this outcome measure was planned to be analyzed for the combined population of participants who received Dupilumab.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis | -1.39 centimeters | Standard Error 0.24 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis | -4.32 centimeters | Standard Error 0.19 |
Secondary
Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores
The SNOT-22 is a validated questionnaire that was used to assess the impact of CRSwNP on HRQoL. It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores | -9.06 score on a scale | Standard Error 1.61 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores | -30.42 score on a scale | Standard Error 1.65 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores | -29.79 score on a scale | Standard Error 1.64 |
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-25.45, -17.27]ANCOVA
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-24.81, -16.65]ANCOVA
Secondary
Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma
ACQ-6 had 6 questions which assessed the most common asthma symptoms (woken by asthma, symptoms on waking, activity limitation, shortness of breath, wheezing, puffs/inhalations use). Participants were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale ranged from 0 = no impairment to 6 = maximum impairment. The ACQ-6 score was the mean of the scores of all 6 questions and therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled), with higher scores indicated lower asthma control. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment, asthma status, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on a subset of participants which included all randomized participants with Asthma and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma | 0.12 score on a scale | Standard Error 0.1 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma | -0.76 score on a scale | Standard Error 0.1 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma | -0.83 score on a scale | Standard Error 0.1 |
Secondary
Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score
The EQ-5D was a standardized HRQoL questionnaire consisting of EQ-5D descriptive system and EQ VAS. The EQ-5D descriptive system comprised of 5 dimensions: mobility, selfcare, usual activities, pain/discomfort and anxiety/depression. Each dimension had 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ VAS recorded the participant's self-rated health on a vertical VAS that allowed them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score | 1.38 score on a scale | Standard Error 1.6 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score | 11.98 score on a scale | Standard Error 1.63 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score | 13.14 score on a scale | Standard Error 1.62 |
Secondary
Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma | -0.18 liters | Standard Error 0.05 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma | 0.10 liters | Standard Error 0.05 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma | 0.06 liters | Standard Error 0.05 |
Secondary
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score
NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score | -0.37 score on a scale | Standard Error 0.08 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score | -1.48 score on a scale | Standard Error 0.08 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score | -1.36 score on a scale | Standard Error 0.07 |
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-1.3, -0.92]ANCOVA
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-1.18, -0.8]ANCOVA
Secondary
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma
NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting ANCOVA model with corresponding baseline, treatment group, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma | -0.34 score on a scale | Standard Error 0.09 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma | -1.51 score on a scale | Standard Error 0.09 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma | -1.44 score on a scale | Standard Error 0.09 |
Secondary
Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery
NC symptom severity was assessed by the participants on a daily basis from Visit 1 and throughout the study using an e-diary on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicated more severity. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on a subset of participants which included all randomized participants with prior NP surgery history.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -0.25 score on a scale | Standard Error 0.1 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -1.54 score on a scale | Standard Error 0.1 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -1.35 score on a scale | Standard Error 0.09 |
Secondary
Change From Baseline at Week 52 in Nasal Polyp Score
NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded based on polyp size from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS means and SE were obtained from ANCOVA model described in Statistical Analysis Overview.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population. Here, overall number of participants analyzed= participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Nasal Polyp Score | 0.16 score on a scale | Standard Error 0.15 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Nasal Polyp Score | -2.05 score on a scale | Standard Error 0.15 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Nasal Polyp Score | -2.24 score on a scale | Standard Error 0.15 |
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-2.59, -1.83]ANCOVA
Comparison: Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates. Statistical inference obtained from all imputed data was combined using Rubin's rule.p-value: <0.000195% CI: [-2.78, -2.03]ANCOVA
Secondary
Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma
NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.
Time frame: Baseline, Week 52
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma | 0.29 score on a scale | Standard Error 0.2 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma | -2.25 score on a scale | Standard Error 0.2 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma | -2.34 score on a scale | Standard Error 0.2 |
Secondary
Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery
NPS was the sum of right and left nostril scores, as evaluated by means of nasal endoscopy. For each nostril, NPS was graded from 0 to 4 (0 = no polyps to 4 = large polyps causing complete obstruction of the inferior nasal cavity), with a lower score indicating smaller-sized polyps. Total NPS was the sum of right and left nostril scores and ranges from 0 (no polyp) to 8 (large polyp), with highest score representing more severe disease. NPS was assessed by centralized, blinded, independent review of the nasal endoscopy video recordings. Data were analyzed using a hybrid method of the WOCF and MI. LS mean and SE were obtained from ANCOVA model.
Time frame: Baseline, Week 52
Population: Analysis was performed on a subset of participants which included all randomized participants with prior NP surgery history and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery | 0.21 score on a scale | Standard Error 0.21 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -2.22 score on a scale | Standard Error 0.22 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -2.56 score on a scale | Standard Error 0.21 |
Secondary
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score
The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score | 0.11 score on a scale | Standard Error 0.37 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score | -5.60 score on a scale | Standard Error 0.37 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score | -6.83 score on a scale | Standard Error 0.37 |
Secondary
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma
The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on a subset of participants which included all randomized participants with asthma and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma | -0.20 score on a scale | Standard Error 0.46 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma | -6.23 score on a scale | Standard Error 0.45 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma | -7.22 score on a scale | Standard Error 0.47 |
Secondary
Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery
The LMK scoring system rated each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score was the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease. Data were analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline, treatment group, asthma/NSAID-ERD status, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on a subset of participants which included all randomized participants with prior NP surgery history and had available data for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -0.06 score on a scale | Standard Error 0.5 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -6.01 score on a scale | Standard Error 0.5 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery | -7.45 score on a scale | Standard Error 0.49 |
Secondary
Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score
Rhinorrhea was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), where higher scores indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score | -0.35 score on a scale | Standard Error 0.07 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score | -1.19 score on a scale | Standard Error 0.07 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score | -1.15 score on a scale | Standard Error 0.07 |
Secondary
Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell
The severity of decreased/loss of sense of smell was reported by the participants using a 0 to 3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms), higher score indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell | -0.18 score on a scale | Standard Error 0.09 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell | -1.49 score on a scale | Standard Error 0.09 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell | -1.29 score on a scale | Standard Error 0.08 |
Secondary
Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score
The UPSIT was a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score | -0.78 score on a scale | Standard Error 0.71 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score | 9.99 score on a scale | Standard Error 0.73 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score | 9.53 score on a scale | Standard Error 0.72 |
Secondary
Change From Baseline at Week 52 in Total Symptom Score
The TSS was the sum of participant-assessed nasal symptom scores for NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (anterior/posterior nasal discharge), each accessed on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranged from 0 (no symptoms) to 9 (severe symptoms). Higher score indicated more severe symptoms. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Total Symptom Score | -0.93 score on a scale | Standard Error 0.2 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Total Symptom Score | -4.17 score on a scale | Standard Error 0.2 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Total Symptom Score | -3.79 score on a scale | Standard Error 0.2 |
Secondary
Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis
The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters VAS the answer to the question, How troublesome are your symptoms of your rhinosinusitis? The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome), where higher score indicated worse thinkable troublesome. Data was analyzed using a hybrid method of the WOCF and MI. The imputed completed data were analyzed by fitting an ANCOVA model with corresponding baseline value, treatment group, asthma/NSAID-ERD status, prior surgery history, and regions as covariates.
Time frame: Baseline, Week 52
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis | -0.93 centimeters | Standard Error 0.26 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis | -4.39 centimeters | Standard Error 0.26 |
| Dupilumab 300 mg q2w | Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis | -4.74 centimeters | Standard Error 0.26 |
Secondary
Functional Dupilumab Concentration in Serum
Time frame: Baseline, Week 2, Week 4, Week 16, Week 24, Week 40, End of treatment (Week 52), End of study (Week 64)
Population: Analysis performed on pharmacokinetics population (PK) which included all participants who received at least 1 dose of IMP with at least 1 evaluable functional dupilumab concentration result. Here, 'number analyzed' = number of participants with available data for each time point. PK data was not collected and assessed for the placebo arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Functional Dupilumab Concentration in Serum | Baseline | 0.00 nanogram/milliliter | Standard Deviation 0 |
| Placebo | Functional Dupilumab Concentration in Serum | Week 2 | 21545.79 nanogram/milliliter | Standard Deviation 9120.36 |
| Placebo | Functional Dupilumab Concentration in Serum | Week 4 | 33760.62 nanogram/milliliter | Standard Deviation 16419.72 |
| Placebo | Functional Dupilumab Concentration in Serum | Week 16 | 70503.07 nanogram/milliliter | Standard Deviation 31234.86 |
| Placebo | Functional Dupilumab Concentration in Serum | Week 24 | 75929.41 nanogram/milliliter | Standard Deviation 35466 |
| Placebo | Functional Dupilumab Concentration in Serum | Week 40 | 21052.06 nanogram/milliliter | Standard Deviation 18588.68 |
| Placebo | Functional Dupilumab Concentration in Serum | Week 52 | 17276.13 nanogram/milliliter | Standard Deviation 16353.2 |
| Placebo | Functional Dupilumab Concentration in Serum | Week 64 | 53.60 nanogram/milliliter | Standard Deviation 160.53 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Functional Dupilumab Concentration in Serum | Week 64 | 851.30 nanogram/milliliter | Standard Deviation 2682.21 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Functional Dupilumab Concentration in Serum | Baseline | 0.00 nanogram/milliliter | Standard Deviation 0 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Functional Dupilumab Concentration in Serum | Week 24 | 79890.06 nanogram/milliliter | Standard Deviation 35361.97 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Functional Dupilumab Concentration in Serum | Week 2 | 22285.67 nanogram/milliliter | Standard Deviation 8459.01 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Functional Dupilumab Concentration in Serum | Week 52 | 75872.58 nanogram/milliliter | Standard Deviation 34127.85 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Functional Dupilumab Concentration in Serum | Week 4 | 37326.31 nanogram/milliliter | Standard Deviation 14226.12 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Functional Dupilumab Concentration in Serum | Week 40 | 80526.37 nanogram/milliliter | Standard Deviation 34048.41 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Functional Dupilumab Concentration in Serum | Week 16 | 74382.04 nanogram/milliliter | Standard Deviation 33118.68 |
Secondary
Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period
SCS included: betamethasone, deflazacort, dexamethasone, dexamethasone sodium phosphate, hydrocortisone, meprednisone, methylprednisolone, methylprednisolone sodium succinate, prednisolone, prednisolone sodium succinate, prednisone, stelamin, triamcinolone, and triamcinolone acetonide. For every participant, the total dose was calculated as (prescribed total daily dose\*duration of SCS use). Then, mean of the total dose of 64 participants (placebo group), 17 participants (dupilumab 300 mg q2w then q4w) and 22 participants (dupilumab 300 mg q2w) was derived.
Time frame: Baseline to Week 52
Population: The analysis was performed on ITT population. Here, overall number of participants analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period | 547.56 milligrams | Standard Deviation 665.4 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period | 282.38 milligrams | Standard Deviation 243.15 |
| Dupilumab 300 mg q2w | Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period | 389.68 milligrams | Standard Deviation 502.61 |
Secondary
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation
An Adverse Event (AE) was defined as any untoward medical occurrence that did not necessarily have to have a causal relationship with the study treatment. TEAEs were defined as AEs that developed or worsened in grade or became serious during TEAE period which was defined as the period from the time of first dose of drug until 84 days following the last administration of drug. SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.
Time frame: Baseline up to 84 days after last dose of study drug (up to 64 weeks)
Population: Analysis was performed on safety population which included all participants who received at least 1 dose or part of a dose of the investigational medicinal product (IMP), analyzed according to the treatment actually received.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | TEAE leading to treatment discontinuation | 17 Participants |
| Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any TEAE | 138 Participants |
| Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any TEAE leading to death | 0 Participants |
| Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any treatment emergent SAE | 16 Participants |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any TEAE leading to death | 1 Participants |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | TEAE leading to treatment discontinuation | 2 Participants |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any treatment emergent SAE | 12 Participants |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any TEAE | 134 Participants |
| Dupilumab 300 mg q2w | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | TEAE leading to treatment discontinuation | 6 Participants |
| Dupilumab 300 mg q2w | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any treatment emergent SAE | 8 Participants |
| Dupilumab 300 mg q2w | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any TEAE leading to death | 0 Participants |
| Dupilumab 300 mg q2w | Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation | Any TEAE | 125 Participants |
Secondary
Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA)
ADA response were categorized as: treatment emergent and treatment boosted response. 1) Treatment emergent was defined as a positive response in the ADA assay post first dose, when baseline results are negative or missing. 2) Treatment boosted was defined as: an ADA positive response in the assay post first dose that is greater-than or equal to 4-fold over baseline titer levels, when baseline results are positive.
Time frame: Baseline to Week 52
Population: The analysis was performed on ADA population which included participants who received at least 1 dose of IMP with at least one evaluable ADA serum sample that was assayed successfully in the ADA assay (either 'ADA negative' or 'ADA positive') following the first dose of the study medication.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA) | With treatment-emergent ADA | 6 Participants |
| Placebo | Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA) | With treatment-boosted ADA | 1 Participants |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA) | With treatment-emergent ADA | 18 Participants |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA) | With treatment-boosted ADA | 0 Participants |
| Dupilumab 300 mg q2w | Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA) | With treatment-emergent ADA | 8 Participants |
| Dupilumab 300 mg q2w | Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA) | With treatment-boosted ADA | 0 Participants |
Secondary
Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method
Rescue treatment was defined as usage of systemic corticosteroids (SCS) or NP surgery (actual or planned) during the treatment period. Rescue treatment included: * SCS: betamethasone, deflazacort, dexamethasone, dexamethasone sodium phosphate, hydrocortisone, meprednisone, methylprednisolone, methylprednisolone sodium succinate, prednisolone, prednisolone sodium succinate, prednisone, stelamin, triamcinolone, and triamcinolone acetonide. * Sino-nasal surgery for nasal polyps when there was worsening of signs and/or symptoms during the study. Estimate of percentage of participants with event by Week 52 was obtained using Kaplan-Meier method.
Time frame: Baseline up to 52 weeks
Population: Analysis was performed on ITT population. Data for this outcome measure was planned to be collected and analyzed for the pooled population of participants receiving Dupilumab.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method | SCS treatment | 42.5 percentage of participants with event |
| Placebo | Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method | NP surgery | 28.3 percentage of participants with event |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method | SCS treatment | 13.1 percentage of participants with event |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method | NP surgery | 5.5 percentage of participants with event |
Secondary
Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant
Rescue treatment was defined as usage of SCS or NP surgery (actual or planned) during the treatment period. SCS Rescue intake duration was defined as the duration (in days) from start of SCS rescue medication till the end of SCS rescue treatment.
Time frame: Baseline to Week 52
Population: Analysis was performed on ITT population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant | 19.58 days | Standard Deviation 17.67 |
| Dupilumab 300 mg (24 Weeks Pooled Arm) | Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant | 10.71 days | Standard Deviation 9 |
| Dupilumab 300 mg q2w | Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant | 23.23 days | Standard Deviation 55.23 |